user_id,pmid_id,selection,annotation,outcome,comparator,intervention,invalid prompt,prompt reason
b'krystie',b'22419941',b'Cannot tell based on the abstract',b'',"b' ""Patients with complete healing at 3 months"" '","b' ""2-component bandage"" '","b' ""Compression stocking"" '",b'0',b''
b'krystie',b'22419941',b'Invalid Prompt',b'',"b'  ""Patients with complete healing at 3 months""  '","b'  ""2-component bandage""  '","b'  ""Compression stocking""  '",b'1',b' The text does not specify whether the patients healed entirely after 12 weeks. and it does not directly correlate compression stockings versus 2-component bandage.'
b'krystie',b'18472878',b'Cannot tell based on the abstract',b'',"b' ""Respiratory distress syndrome"" '","b' ""No macrolide"" '","b' ""Any macrolide"" '",b'0',b''
b'krystie',b'18472878',b'Invalid Prompt',b'',"b'  ""Respiratory distress syndrome""  '","b'  ""No macrolide""  '","b'  ""Any macrolide""  '",b'1',"b' There is no mention of respiratory distress syndrome in the abstract, and no access to the rest of the document was given.'"
b'krystie',b'22162919',b'Cannot tell based on the abstract',b'',"b' ""Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks\' gestation or more) (ALL)"" '","b' ""Control (daily)"" '","b' ""Intermittent iron"" '",b'0',b''
b'krystie',b'22162919',b'Cannot tell based on the abstract',b'',"b' ""Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks\' gestation or more) (ALL)"" '","b' ""Control (daily)"" '","b' ""Intermittent iron"" '",b'0',b''
b'krystie',b'22162919',b'No significant difference',b'No significant difference was observed with respect to pregnancy or birth outcome across the groups.',"b' ""Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks\' gestation or more) (ALL)"" '","b' ""Control (daily)"" '","b' ""Intermittent iron"" '",b'0',b''
b'krystie',b'19066176',b'Significantly increased',"b'The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p\xe2\x80\x8a=\xe2\x80\x8a0.059) in the golimumab 100 mg plus placebo group, 55.1% (p\xe2\x80\x8a=\xe2\x80\x8a0.001) in the golimumab 50 mg plus methotrexate group and 56.2% (p<0.001) in the golimumab 100 mg plus methotrexate group. At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p\xe2\x80\x8a=\xe2\x80\x8a0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.'","b' ""HAQ Change \xe2\x89\xa5.22 (14 wk)"" '","b' ""Placebo"" '","b' ""Golimumab"" '",b'0',b''
b'krystie',b'21503263',b'Cannot tell based on the abstract',b'',"b' ""Patients with \xe2\x89\xa5 1 serious adverse event (non-fatal)"" '","b' ""placebo"" '","b' ""tiotropium"" '",b'0',b''
b'krystie',b'21503263',b'Invalid Prompt',b'',"b'  ""Patients with \xe2\x89\xa5 1 serious adverse event (non-fatal)""  '","b'  ""placebo""  '","b'  ""tiotropium""  '",b'1',b' There were no conclusions available as to determine whether serious non-fatal adverse effects were present using tiotropium versus placebo.'
b'krystie',b'18472878',b'No significant difference',"b'No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.'","b' ""Perinatal mortality"" '","b' ""No macrolide"" '","b' ""Any macrolide"" '",b'0',b''
b'krystie',b'19066176',b'Cannot tell based on the abstract',b'',"b' ""All Withdrawals (14-24 wk)"" '","b' ""Placebo"" '","b' ""Golimumab"" '",b'0',b''
b'krystie',b'19066176',b'Invalid Prompt',b'',"b'  ""All Withdrawals (14-24 wk)""  '","b'  ""Placebo""  '","b'  ""Golimumab""  '",b'1',"b'There is no clear distinction referring to ""all withdrawals"" at 14-24 weeks for patients receiving Golimumab and those receiving Placebo. '"
b'krystie',b'15450119',b'Cannot tell based on the abstract',b'',"b' ""Perinatal death"" '","b' ""Prostaglandin"" '","b' ""Misoprostol"" '",b'0',b''
b'krystie',b'15450119',b'No significant difference',"b'Neonatal Outcomes\n\nMisoprostol n = 80 (%)\tDinoprostone n = 83 (%)\tStatistical significance,Perinatal death\t0\t1(1.2%)\tNS'","b'  ""Perinatal death""  '","b'  ""Prostaglandin""  '","b'  ""Misoprostol""  '",b'0',b''
b'krystie',b'17176461',b'Cannot tell based on the abstract',b'',"b' ""Oxytocin augmentation"" '","b' ""Control"" '","b' ""Epidural analgesia"" '",b'0',b''
b'krystie',b'17176461',b'No significant difference',"b'Administration of epidural analgesia with 1% lidocaine do not prolong the active-first or second stages of labor significantly, and do not increase the incidence of oxytocin augmentation,Labor progress\tEpidural N = 197\tMeperidine N = 198\tP value,Oxytocin augmentation After initiation of Analgesia\t197(100)\t192(96)\tNS'","b'  ""Oxytocin augmentation""  '","b'  ""Control""  '","b'  ""Epidural analgesia""  '",b'0',b''
b'krystie',b'22066097',b'Invalid Prompt',b'',"b' ""Live birth rate per woman randomised"" '","b' ""GnRH agonist"" '","b' ""GnRH antagonist"" '",b'1',"b"" The study's purpose is to evaluate the comparative therapeutic efficacy of radiofrequency ablation (RFA) and hepatic resection for the treatment of colorectal liver metastasis (CRLM).\n\nNo comparison between GnRH antagonist or GnRH agonist was made."""
b'krystie',b'22080588',b'Significantly increased',"b'Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9\xe2\x80\x9312: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7\xe2\x80\x939.4; p < .0001) and through 24 weeks follow-up (Weeks 9\xe2\x80\x9324: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6\xe2\x80\x937.5; p < .0001).'","b' ""Continuous or sustained abstinence at longest follow-up (24+ weeks)"" '","b' ""Control"" '","b' ""Varenicline"" '",b'0',b''
b'krystie',b'20200301',b'Cannot tell based on the abstract',b'',"b' ""Percentage of participants having at least one severe hypoglycaemic event"" '","b' ""Glargine"" '","b' ""Detemir"" '",b'0',b''
b'krystie',b'20200301',b'No significant difference',b'Risk of hypoglycemia was comparable between treatments with \xe2\x88\xbc30% of patients experiencing symptomatic hypoglycemia with PG \xe2\x89\xa43.1 mmol/l in either group',"b'  ""Percentage of participants having at least one severe hypoglycaemic event""  '","b'  ""Glargine""  '","b'  ""Detemir""  '",b'0',b''
b'krystie',b'19284644',b'Cannot tell based on the abstract',b'',"b' ""Death or severe brain injury by first hospital discharge"" '","b' ""Liberal"" '","b' ""Restrictive"" '",b'0',b''
b'krystie',b'19284644',b'Invalid Prompt',b'',"b'  ""Death or severe brain injury by first hospital discharge""  '","b'  ""Liberal""  '","b'  ""Restrictive""  '",b'1',b' There was no mention of any of the requested items.'
b'krystie',b'19066176',b'Cannot tell based on the abstract',b'',"b' ""Serious Infections (16-24 wk)"" '","b' ""Placebo"" '","b' ""Golimumab"" '",b'0',b''
b'krystie',b'19066176',b'Cannot tell based on the abstract',b'',"b' ""Serious Infections (16-24 wk)"" '","b' ""Placebo"" '","b' ""Golimumab"" '",b'0',b''
b'krystie',b'19066176',b'Significantly increased',"b'Patients in the golimumab groups had greater incidences of infections than those in the methotrexate-alone group. Also, patients in the 100 mg golimumab plus methotrexate group had greater incidences of serious adverse events and serious infections than those in the other groups. One patient who received golimumab 100 mg alone died because of a serious infection.'","b'  ""Serious Infections (16-24 wk)""  '","b'  ""Placebo""  '","b'  ""Golimumab""  '",b'0',b''
b'krystie',b'20831782',b'Cannot tell based on the abstract',b'',"b' ""Infiltration"" '","b' ""Routine replacement"" '","b' ""Clinically indicated"" '",b'0',b''
b'krystie',b'20831782',b'No significant difference',"b'Infiltration, n (%)\t53 (30%)\t61 (33%)\tRR 1.10 (0.81, 1.49), p = 0.57,There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43). No cases of local infection or IVD-related bloodstream infection occurred in either group.'","b'  ""Infiltration""  '","b'  ""Routine replacement""  '","b'  ""Clinically indicated""  '",b'0',b''
b'krystie',b'21503263',b'Cannot tell based on the abstract',b'',"b' ""Patients with \xe2\x89\xa5 1 exacerbation"" '","b' ""placebo"" '","b' ""tiotropium"" '",b'0',b''
b'krystie',b'21503263',b'Invalid Prompt',b'',"b'  ""Patients with \xe2\x89\xa5 1 exacerbation""  '","b'  ""placebo""  '","b'  ""tiotropium""  '",b'1',b'The results section was missing from the article. There is no way to accurately describe whether the patients had one or more exacerbations using tiotropium versus placebo during the study.'
b'krystie',b'20427683',b'Significantly increased',"b'In the intention-to-treat analysis, complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up: 25/48 (52%) in the HBOT group and 12/42 (29%) in the placebo group (P = 0.03). In a sub-analysis of those patients completing >35 HBOT sessions, healing of the index ulcer occurred in 23/38 (61%) in the HBOT group and 10/37 (27%) in the placebo group (P = 0.009).,The HODFU study showed that adjunctive treatment with HBOT facilitates healing of chronic foot ulcers in selected patients with diabetes.'","b' ""Healed at end of treatment (6 weeks)"" '","b' ""Control"" '","b' ""HBOT"" '",b'0',b''
b'krystie',b'19066176',b'Cannot tell based on the abstract',b'',"b' ""HAQ Change \xe2\x89\xa5.22 (14 wk)"" '","b' ""Placebo"" '","b' ""Golimumab"" '",b'0',b''
b'krystie',b'19066176',b'Significantly increased',"b'Thirty-three per cent of patients in group 1 achieved an ACR20 response at week 14 compared with 55.6% (p<0.001) in the combined groups 3 and 4, representing 55.1% (p\xe2\x80\x8a=\xe2\x80\x8a0.001) in group 3 and 56.2% (p<0.001) in group 4,Improvement from baseline in HAQ-DI\t\xe2\x88\x920.13 (\xe2\x88\x920.38 to 0.13)\t\xe2\x88\x920.25 (\xe2\x88\x920.63 to 0.13)\t\xe2\x88\x920.38 (\xe2\x88\x920.75 to \xe2\x88\x920.13)\t\xe2\x88\x920.38 (\xe2\x88\x920.63 to \xe2\x88\x920.13)\t\xe2\x88\x920.38 (\xe2\x88\x920.75 to \xe2\x88\x920.13)'","b'  ""HAQ Change \xe2\x89\xa5.22 (14 wk)""  '","b'  ""Placebo""  '","b'  ""Golimumab""  '",b'0',b''
b'krystie',b'15450119',b'Cannot tell based on the abstract',b'',"b' ""Vaginal delivery not achieved within 24 hours"" '","b' ""Prostaglandin"" '","b' ""Misoprostol"" '",b'0',b''
b'krystie',b'15450119',b'Significantly decreased',"b'With misoprostol, more women delivered within 12 h (57.5% vs. 32.5%, p < 0.01) and almost all of the women delivered within 24 h (98.8% vs. 91.6%, p < 0.05).'","b'  ""Vaginal delivery not achieved within 24 hours""  '","b'  ""Prostaglandin""  '","b'  ""Misoprostol""  '",b'0',b''
